3073c410-3a7e-42e4-a67a-3884840c49f4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- BILE_ACID_METABOLISM+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- ANGIOGENESIS+0.100
- APICAL_SURFACE+0.100
- COAGULATION+0.100
- INFLAMMATORY_RESPONSE+0.100
- INTERFERON_ALPHA_RESPONSE+0.100
- INTERFERON_GAMMA_RESPONSE+0.100
Top 10 suppressed
- E2F_TARGETS-0.500
- MTORC1_SIGNALING-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- ADIPOGENESIS-0.300
- DNA_REPAIR-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0099982 | — | — | 0.887 |
| 2 | BS_94MT16N2 | pilocytic astrocytoma | — | 0.877 |
| 3 | sclcMAD11162_S44.txt | — | cohortA1 | 0.873 |
| 4 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.873 |
| 5 | C3N-03038 | — | cohortA1 | 0.871 |
| 6 | SRR1476407 | GTEX | — | 0.866 |
| 7 | BS_J71N7D09 | Med | Medulloblastoma | 0.865 |
| 8 | SRR1486863 | GTEX | — | 0.864 |
| 9 | BS_YZ2Z1Q6Y | pilocytic astrocytoma | — | 0.863 |
| 10 | SRR1444876 | GTEX | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |